Fenofibrate is clinically used to treat dyslipidemia via activation of PPARα, and also inhibited the cytopathic effect exerted by SARS-CoV-2 on Vero E6 at 20 μM (Figure 3B and Supplementary Table S5). The gene discussed is PPARA; the disease is metabolic syndrome.